News & Events

News

Our latest Press Releases

Tubulis to Present Phase I/IIa Trial Data for ADC Candidate TUB-040 in Platinum-resistant Ovarian Cancer in Rapid Oral Presentation at ASCO 2026

Gilead to Acquire Tubulis Adding Potentially Best-In-Class Antibody-Drug Conjugate and Next Generation Platform to Further Strengthen Oncology Pipeline

Tubulis Adds Steve Kelsey as Independent Director to its Advisory Board

EVENTS

Meet Tubulis live